Yuko Nakayama
Overview
Explore the profile of Yuko Nakayama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
140
Citations
1236
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kohno N, Ishida M, Odaka M, Okanishi H, Tomiuka M, Ariga K, et al.
Mol Clin Oncol
. 2025 Jan;
22(3):26.
PMID: 39885865
Pleomorphic adenoma (PA) is the most common salivary gland tumour. Pre-operative fine-needle aspiration (FNA) is currently one of the most widely used cytological examination techniques for the diagnosis of salivary...
2.
Takahashi K, Kagami Y, Yoshimura R, Morota M, Murakami N, Nakamura S, et al.
Breast Cancer
. 2024 Dec;
32(1):197-207.
PMID: 39630209
Background: To analyze in a prospective study the long-term safety and efficacy of 3-dimensional conformal radiotherapy (3D-CRT) to deliver accelerated partial breast irradiation (APBI) for Japanese women with early breast...
3.
Nakayama Y, Ino A, Yamamoto K, Takara K
Biomed Rep
. 2024 Oct;
21(6):184.
PMID: 39420918
Everolimus is an oral mammalian target of rapamycin (mTOR) inhibitor used in cancer chemotherapy and transplantation. Due to its therapeutic properties, everolimus has been used long-term in clinical practice. Drug...
4.
Komai S, Harai N, Tahara I, Nakayama Y, Tsuchiya K
Cureus
. 2024 Sep;
16(8):e66221.
PMID: 39238765
Thyroid stimulating hormone-secreting pituitary neuroendocrine tumor (TSH-PitNET) is a rare disease in which pituitary adenomas secrete excessive amounts of TSH, and TSH is not suppressed despite high blood levels of...
5.
Nagao A, Murakami N, Sakuramachi M, Kashihara T, Takahashi K, Kaneda T, et al.
Brachytherapy
. 2024 Jun;
23(5):595-603.
PMID: 38942713
Background: To protect the rectum and bladder from high dose exposure, the Japanese guidelines for managing uterine cervical carcinoma recommend pelvic irradiation with central shielding (CS). Conversely, the European Society...
6.
Nakayama Y, Ino A, Yamamoto K, Takara K
Anticancer Res
. 2024 Jun;
44(7):2871-2876.
PMID: 38925842
Background/aim: Everolimus-resistant Caki/EV and 786/EV cells have been established from human derived renal cell carcinoma cells, Caki-2 and 786-O, respectively. These cells exhibit resistance to everolimus and to other mTOR...
7.
Saito R, Kawaida H, Amemiya H, Nakata Y, Izumo W, Furuya M, et al.
Langenbecks Arch Surg
. 2024 Jun;
409(1):173.
PMID: 38836878
Purpose: We retrospectively analyzed pancreatectomy patients and examined the occurrence rate and timing of postoperative complications (time-to-complication; TTC) and their impact on the length of postoperative hospital stay (POHS) to...
8.
Mizuta S, Miyakoshi T, Matsui K, Nakayama Y, Koshida Y
Cureus
. 2024 Apr;
16(3):e57060.
PMID: 38681359
Dimethyl sulfate (DMS) is a drug widely used as a pharmaceutical and synthetic raw material. On the other hand, it is highly toxic and requires management and treatment as a...
9.
Saito R, Kawaida H, Izumo W, Nakata Y, Amemiya H, Ozawa T, et al.
Anticancer Res
. 2024 Apr;
44(5):2141-2149.
PMID: 38677773
Background/aim: Perioperative chemotherapy has become more common in patients with pancreatic cancer (PC), and the significance of lymph node (LN) metastasis and the role of surgical resection in PC have...
10.
Nakayama T, Furuya S, Higuchi Y, Matsuoka K, Saito R, Takahashi K, et al.
Anticancer Res
. 2024 Feb;
44(2):561-565.
PMID: 38307547
Background/aim: Cytoglobin (Cygb), a protein involved in cellular oxygen metabolism and protection, has garnered attention owing to its potential role in the initiation and progression of cancer, particularly colon cancer...